OM:SANION

Stock Analysis Report

Executive Summary

Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Saniona's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.1%

SANION

1.8%

SE Biotechs

1.9%

SE Market


1 Year Return

-24.0%

SANION

-18.0%

SE Biotechs

9.6%

SE Market

Return vs Industry: SANION underperformed the Swedish Biotechs industry which returned -18% over the past year.

Return vs Market: SANION underperformed the Swedish Market which returned 9.6% over the past year.


Shareholder returns

SANIONIndustryMarket
7 Day9.1%1.8%1.9%
30 Day21.0%-1.9%-0.3%
90 Day31.2%-11.7%0.7%
1 Year-21.9%-24.0%-17.5%-18.0%14.3%9.6%
3 Year-33.9%-35.8%29.5%19.2%31.5%11.9%
5 Year199.1%176.3%66.9%68.0%66.2%30.8%

Price Volatility Vs. Market

How volatile is Saniona's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Saniona undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: SANION (SEK23.9) is trading below our estimate of fair value (SEK376.25)

Significantly Undervalued: SANION is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SANION is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SANION is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SANION's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SANION is overvalued based on its PB Ratio (8.3x) compared to the SE Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Saniona forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

72.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SANION is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SANION is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SANION is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SANION's revenue (48.7% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: SANION's revenue (48.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if SANION's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Saniona performed over the past 5 years?

-37.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SANION is unprofitable, and losses have increased over the past 5 years at a rate of -37.7% per year.

Accelerating Growth: Unable to compare SANION's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SANION is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.4%).


Return on Equity

High ROE: SANION has a negative Return on Equity (-76.22%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SANION is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SANION is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Saniona's financial position?


Financial Position Analysis

Short Term Liabilities: SANION's short term assets (SEK110.3M) exceeds its short term liabilities (SEK59.4M)

Long Term Liabilities: SANION's short term assets (110.3M) exceeds its long term liabilities (2.9M)


Debt to Equity History and Analysis

Debt Level: SANION's debt to equity ratio (15.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if SANION's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: SANION has a low level of unsold assets or inventory.

Debt Coverage by Assets: SANION's debt is covered by short term assets (assets are 10.506850x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SANION has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SANION has less than a year of cash runway if free cash flow continues to reduce at historical rates of -40% each year


Next Steps

Dividend

What is Saniona's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SANION's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SANION's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SANION's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SANION's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SANION's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Saniona's salary, the management and board of directors tenure and is there insider trading?

8.8yrs

Average management tenure


CEO

Jørgen Drejer (64yo)

5.8yrs

Tenure

kr1,687,000

Compensation

Mr. Jørgen Drejer, Ph.D., founded Saniona AB (Alternate name-Aniona) in 2011 and has been its Chief Executive Officer since 2014. Mr. Drejer is a Co-founder of NeuroSearch. He has been Member of the Execut ...


CEO Compensation Analysis

Compensation vs. Market: Jørgen's total compensation ($USD171.63K) is about average for companies of similar size in the Swedish market ($USD124.61K).

Compensation vs Earnings: Jørgen's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

8.8yrs

Average Tenure

62.5yo

Average Age

Experienced Management: SANION's management team is seasoned and experienced (8.8 years average tenure).


Board Age and Tenure

2.9yrs

Average Tenure

64yo

Average Age

Experienced Board: SANION's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Claus Bræstrup (74yo)

    Co-Founder & Director

    • Tenure: 5.8yrs
  • Jørgen Drejer (64yo)

    Co-Founder

    • Tenure: 5.8yrs
    • Compensation: kr1.69m
  • Thomas Feldthus (59yo)

    Co-Founder

    • Tenure: 8.8yrs
    • Compensation: kr2.20m
  • Palle Christophersen (61yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 8.8yrs
    • Compensation: kr1.35m
  • Karin Nielsen

    Vice President of Operations and Director of In Vivo Pharmacology

    • Tenure: 3.6yrs

Board Members

  • Don deBethizy (69yo)

    Chairman of the Board

    • Tenure: 1.8yrs
    • Compensation: kr1.15m
  • Claus Bræstrup (74yo)

    Co-Founder & Director

    • Tenure: 5.8yrs
  • Carl Sundberg (61yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: kr145.00k
  • Jørgen Drejer (64yo)

    Co-Founder

    • Tenure: 5.8yrs
    • Compensation: kr1.69m
  • Ed Saltzman (64yo)

    Director

    • Tenure: 0.4yrs
  • Anna Ljung (39yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: kr184.00k

Company Information

Saniona AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Saniona AB (publ)
  • Ticker: SANION
  • Exchange: OM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr663.544m
  • Shares outstanding: 27.76m
  • Website: https://www.saniona.com

Number of Employees


Location

  • Saniona AB (publ)
  • Baltorpvej 154
  • Ballerup
  • Capital Region of Denmark
  • 2750
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SANIONOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKApr 2014
0RQJLSE (London Stock Exchange)YesShare CapitalGBSEKApr 2014
30SDB (Deutsche Boerse AG)YesShare CapitalDEEURApr 2014

Biography

Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug can ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 21:31
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.